Cargando…
Editorial: Apatinib and Anlotinib in the Treatment of Radioactive Iodine Refractory and Highly Invasive Thyroid Carcinoma
Autores principales: | Jia, Wenqing, Liu, Zhuoran, Zhan, Ling, Zhao, Qiwu, Qiu, Weihua, Kuang, Jie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9657471/ https://www.ncbi.nlm.nih.gov/pubmed/36362609 http://dx.doi.org/10.3390/jcm11216380 |
Ejemplares similares
-
Identification of Radioactive Iodine Refractory Differentiated Thyroid Cancer
por: Mu, Zhuan-Zhuan, et al.
Publicado: (2019) -
Apatinib vs Placebo in Patients With Locally Advanced or Metastatic, Radioactive Iodine–Refractory Differentiated Thyroid Cancer: The REALITY Randomized Clinical Trial
por: Lin, Yansong, et al.
Publicado: (2021) -
Quantitative thyroglobulin response to radioactive iodine treatment in predicting radioactive iodine-refractory thyroid cancer with pulmonary metastasis
por: Wang, Chen, et al.
Publicado: (2017) -
Radioactive Iodine-Refractory Differentiated Thyroid Cancer and Redifferentiation Therapy
por: Liu, Jierui, et al.
Publicado: (2019) -
The efficacy and safety in radioactive iodine refractory thyroid cancer patients treated with sorafenib
por: Ling, Yuanna, et al.
Publicado: (2023)